HomeNewsTrendsHealthIndia should do away with restrictions once Delta is less than 1% of tested samples, says ICMR's JP Muliyil

India should do away with restrictions once Delta is less than 1% of tested samples, says ICMR's JP Muliyil

"Coronavirus infections may keep causing flu-like symptoms but that should not be too much of a worry given our history of high degree of natural infection and vaccination"

February 04, 2022 / 10:45 IST
Story continues below Advertisement

Dr J P Muliyil, who is chairman of scientific advisory committee at ICMR National Institute of Epidemiology and a member of the COVID working group of the National Technical Advisory Group of Immunisation, suggests that the Omicron may be ending and that it may be prudent for India to do away with COVID restrictions once Delta variant’s share in tested samples is less than 1 per cent.

Edited excerpts:

Story continues below Advertisement

With the third COVID-19 wave looking to stabilise in India, what can we expect in the days ahead? Can there be any more variants which may cause a fresh trigger?

All possibilities are there. There are already two Omicron lineages, BA 1 and BA2, sweeping through populations in most countries. But this third wave in India has, in a way, assured that, with a very high degree of previous infection and good COVID vaccination coverage, the infection caused by new variants - if any - may stay mild. All the existing COVID vaccines have largely been able to prevent severe disease and deaths even though fresh variants like Omicron have kept infecting people who may have received even four doses of the vaccines. But you have to understand that infection, in itself, means nothing if there is near zero risk of hospitalisation and death.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show